ABSTRACT

Guillain-Barré Syndrome (GBS) is a rare but potentially life-threatening autoimmune condition marked by the sudden onset of muscle weakness and, in some cases, paralysis. This syndrome often develops following an infection, particularly of the respiratory or gastrointestinal tract, and is thought to result from a dysregulated immune response in which the body’s immune system mistakenly targets the peripheral nervous system. The clinical course of GBS is highly variable, typically presenting with ascending paralysis, sensory changes, and autonomic dysfunction. At the core of its pathophysiology is the demyelination of peripheral nerves, which disrupts normal nerve conduction. Diagnosis is primarily based on clinical findings, with supportive confirmation through lumbar puncture and electrophysiological studies. Although most individuals with GBS recover, the recovery process can be lengthy, and severe cases may lead to permanent disability or even death. Therapeutic interventions, such as intravenous immunoglobulin (IVIg) therapy and plasmapheresis, focus on reducing symptom severity and accelerating recovery. Keywords: Guillain-Barre syndrome, Weakness, Paralysis, Infection and Immunoglobulin
Publication date: 01/04/2026

https://www.ijbpas.com/pdf/2026/April/MS_IJBPAS_2026_10063.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.4.10063